AVM Biotechnology

Executive Summary

AVM Biotechnology is a Seattle-based clinical-stage biotech developing AVM0703, a proprietary high-dose dexamethasone formulation designed to mobilize unique gamma delta and invariant T cells to treat cancer and autoimmune diseases. The company aims to harness the innate immune system to deliver effective, safe, and accessible therapies. Founded in 2010, AVM is currently in the pre-clinical stage, focusing on advancing AVM0703 toward clinical trials. Its differentiated mechanism of action could address unmet needs in oncology and autoimmune disorders, though the early-stage nature entails significant development risks. The company is privately held with no public disclosures on financing or valuation.

Upcoming Catalysts (preview)

• Q3 2026IND Filing for AVM070360% success
• Q4 2026First Clinical Trial Initiation50% success
• Q2 2026Preclinical Proof-of-Concept Data Publication70% success